Tissue Phenomics Blog

5B_Her2-classified.jpg

Posts by Topic

see all

Topics:  personalized medicine, companion diagnostics, reimbursement, market access, quantitative IHC

Enabling Market Access for Quantitative IHC-Based Companion Diagnostics

Jun 5, 2017 6:00:00 AM

The complexity of the tumor microenvironment represents a significant challenge to the personalized medicine movement in the field of oncology. While genetic and genomic analyses enable an understanding of the patient’s genotype, this does not necessarily translate to active tumor microenvironment expression – phenomics – through which pharmacodynamic pathways are modulated by targeted therapies. Similarly, while single biomarker immunohistochemistry (IHC) can effectively quantify expression of a particular biomarker, it fails to evaluate the entire picture of the tumor microenvironment, where a myriad of potentially confounding factors exists to distort the causal relationship between expression of a single marker and treatment response. 

Enter context-based analysis of biomarker expression – quantitative, multiplex IHC technology leveraging “big data” capabilities to overcome the inherent limitations of existing diagnostic techniques and more precisely assess the tumor microenvironment. Applied as a companion diagnostic (CDx), quantitative IHC or IF (qIHC/IF) using image analysis (IA) technology represents a potentially paradigm-shifting approach to predict patient response to oncologics and thus bring the movement of personalized medicine to fruition. Read More